Prevention of chronic kidney and vascular disease: Toward global health equity - The Bellagio 2004 Declaration

Kidney International, Supplement

Volumn 68, Issue 98, 2005, Pages

  Dirks, John H ^b   De Zeeuw, Dick ^b   Agarwal, Sanjay K ^b   Atkins, Robert C ^b   Correa Rotter, Ricardo ^b   D'Amico, Giuseppe ^b   Bennett, Peter H ^b   El Nahas, Meguid ^b   Valdes, Raul Herrera ^b   Kaseje, Dan ^b   Katz, Ivor J ^b   Naicker, Sarala ^b   Rodriguez Iturbe, Bernardo ^b   Schieppati, Arrigo ^b   Shaheen, Faissal ^b   Sitthi Amorn, Chitr ^b   Solez, Kim ^b   Viberti, Giancarlo ^b   Remuzzi, Giuseppe ^b   Weening, Jan J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Capacity building; Chronic kidney disease; Diabetes; Hypertension; Prevention

Indexed keywords

ALBUMIN; CREATININE; PROTEIN INHIBITOR; RAS INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOSTATISTICS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; DIALYSIS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN INJURY; OUTCOME ASSESSMENT; PATHOGENESIS; PHYSICIAN; POPULATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RENAL REPLACEMENT THERAPY; SMOKING; VASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; ECONOMIC ASPECT; PREVALENCE; RENOVASCULAR DISEASE; REVIEW; RISK FACTOR; CHRONIC KIDNEY FAILURE; ECONOMICS; HEALTH; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; NEPHROLOGY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INTERNATIONAL COOPERATION; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; SOCIETIES, MEDICAL; WORLD HEALTH;

EID: 27944455879     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09800.x     Document Type: Article

References (49)

1. ZIMMET P, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature 414:782-787, 2001
2. GALL MA, BORCH-JOHNSEN K, HOUGAARD P, et al: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309, 1995
3. GERSTEIN HC, MANN JF, YI Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
4. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
5. KHER V: End-stage renal disease in developing countries. Kidney Int 62:350-362, 2002
6. LYSAGHT MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13(Suppl 1):S37-S40, 2002
7. RITZ E, RYCHLIK I, LOCATELLI F, HALIMI S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34:795-808, 1999
8. MCFARLANE SI, BANERJI M, SOWERS JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86:713-718, 2001
9. BRENNER BM, MACKENZIE HS: Nephron mass as a risk factor for progression of renal disease. Kidney Int 63(Suppl):S124-S127, 1997
10. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
11. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
12. VIBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106:672-678, 2002
13. GAEDE P, VEDEL P, LARSEN N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
14. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
15. BRUNSKILL NJ: Albumin signals the coming of age of proteinuric nephropathy. J Am Soc Nephrol 15:504-505, 2004
16. ZOJA C, BENIGNI A, REMUZZI G: Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens 13:31-37, 2004
17. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
18. JENSEN JS, FELDT-RASMUSSEN B, STRANDGAARD S, et al: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35:898-903, 2000
19. YUSUF S, SLEIGHT P, POGUE J, et al: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
20. CHUA DC, BAKRIS GL: Is proteinuria a plausible target of therapy? Curr Hypertens Rep 6:177-181, 2004
21. DE ZEEUW D: Albuminuria, just a marker for cardiovascular disease, or is it more? J Am Soc Nephrol 16:1883-1885, 2005
22. DE ZEEUW D, REMUZZI G, PARVING HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65:2309-2320, 2004
23. EKNOYAN G, HOSTETTER T, BAKRIS GL, et al: Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42:617-622, 2003
24. XUE JL, MA JZ, LOUIS TA, COLLINS AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12:2753-2758, 2001
25. WORLD HEALTH ORGANIZATION: Burden of disease. Global burden of disease estimate. Available at: http://www3.who.int/whosis/menu.cfm?path=evidence. burden&language=english. Accessed May 2004
26. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39(Suppl 1):S1-S266, 2002
27. HILLEGE HL, JANSSEN WM, BAK AA, et al: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249:519-526, 2001
28. HILLEGE HL, FIDLER V, DIERCKS GF, et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782, 2002
29. U.S. RENAL DATA SYSTEM: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
30. EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION: Report on the management of renal failure in Europe, XXV, 1995. Nephrol Dial Transplant 11:1-32, 1996
31. BRIGANTI EM, BRANLEY P, CHADBAN SJ, et al: Smoking is associated with renal impairment and proteinuria in the normal population: The AusDiab kidney study. Australian Diabetes, Obesity and Lifestyle Study. Am J Kidney Dis 40:704-712, 2002
32. CHADBAN SJ, BRIGANTI EM, KERR PG, et al: Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 14(Suppl 2):S131-S138, 2003
33. ASCHNER P: Diabetes trends in Latin America. Diabetes Metab Res Rev 18(Suppl 3):S27-S31, 2002
34. NARVA AS: The spectrum of kidney disease in American Indians. Kidney Int (Suppl 83):S3-S7, 2003
35. WANG Z, HOY WE: Hypertension, dyslipidemia, body mass index, diabetes and smoking status in Aboriginal Australians in a remote community. Ethn Dis 13:324-330, 2003
36. PRADEEPA R, MOHAN V: The changing scenario of the diabetes epidemic: Implications for India. Indian J Med Res 116:121-132, 2002
37. WILD S, ROGLIC G, GREEN A, et al: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
38. RUGGENENTI P, PAGANO E, TAMMUZZO L, et al: Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 59:286-294, 2001
39. THOMAS MC, COOPER ME, SHAHINFAR S, BRENNER BM: Dialysis delayed is death prevented: A clinical perspective on the RENAAL study. Kidney Int 63:1577-1579, 2003
40. BOULWARE LE, JAAR BG, TARVER-CARR ME, et al: Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 290:3101-3114, 2003
41. PALMER AJ, ANNEMANS L, ROZE S, et al: An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 18:733-738, 2004
42. VERHAVE JC, GANSEVOORT RT, HILLEGE HL, et al, for the PREVEND Study Group: An elevated urinary albumin excretion predicts de nove development of renal function impairment in the general population. Kidney Int Suppl 92:S18-21, 2004
43. ASSELBERGS FW, DIERCKS GF, HILLEGE HL, et al: Prevention of Renal and Vascular End Stage Disease Intervention Trial (PREVEND IT) investigators. Effects of fosinopril and pravastin on cardiovascular events in microalbuminuric subjects. Circulation 110:2809-2816, 2004
44. MANI MK: Prevention of chronic renal failure at the community level. Kidney Int (Suppl 83):S86-S89, 2003
45. COUNCIL I: Inventing a better future. A strategy for building worldwide capacities in science and technology, 1990.
46. SCHIEPPATI A, REMUZZI G: Fighting renal diseases in poor countries: Building a global fund with the help of the pharmaceutical industry. J Am Soc Nephrol 15(3):704-707, 2004
47. KATIKIREDDI SV: HINARI: Bridging the global information divide. BMJ 328(7449):1190-1193, 2004
48. REAY DS: Virtual solution to carbon cost of conferences. Nature 424(6946):251, 2003
49. Diabetes and Kidney Disease. Time to Act, Brussels, 2003